2seventy bio, Inc. operates as a biotechnology firm specializing in cell and gene therapies, with a primary mission to discover, develop, and commercialize advanced cancer treatments within the U.S. Its pipeline notably includes idecabtagene vicleucel, marketed as ide-cel or Abecma, and bb21217, both of which are CAR-T cell therapeutic candidates specifically designed to address multiple myeloma. The company also maintains a strategic partnership with Bristol-Myers Squibb Company.